ScreenerHero

ATOS Atossa Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · atossatherapeutics.com
2.460USD+0.41%Mkt Cap: 24.55M $P/E: —

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a sele…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap24.55M USD
Enterprise Value-1.64M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-34.77M USD
Revenue/Share—
Last Price2.460 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees16
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.74
PEG—
EV/EBITDA0.04
EV/Revenue—
P/S—
P/B0.91
EPS (TTM)-4.45
EPS (Forward)-3.30
52W Range
1.7004% of range19.35
52W High19.35 USD
52W Low1.700 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-88.35%
ROA-73.03%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.76M USD
CapEx (TTM)23.00K USD
FCF Margin—
FCF Yield-95.04%
Net Debt-26.09M USD
Net Debt/EBITDA0.67
Balance Sheet
Debt/Equity—
Current Ratio5.69
Quick Ratio4.79
Book Value/Sh2.69 USD
Cash/Share2.62 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateApr 20, 2018
Splits
Last Split1:15
Split DateFeb 2, 2026
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)19.00 USD
Upside (mean)+672.4%
Target Range10.00 USD – 25.00 USD
10.00+672.4% to mean25.00
# Analysts3
Ownership
Shares Out.9.98M
Float9.94M
Insiders1.85%
Institutions13.61%
Short Interest
Short Ratio14.0d
Short % Float7.64%
Short % Out.7.64%
Shares Short762.16K
Short (prev mo.)795.46K
Technical
SMA 502.385 (+3.1%)
SMA 2004.649 (-47.1%)
Beta1.27
S&P 52W Chg16.45%
Avg Vol (30d)62.46K
Avg Vol (10d)82.61K
Technical Indicators
RSI (14)56.7
MACD-0.0230
MACD Signal-0.0693
MACD Hist.+0.0463
BB Upper2.671 USD
BB Middle2.267 USD
BB Lower1.864 USD
BB Width35.57%
ATR (14)0.1729 USD
Vol Ratio (20d)0.30x